We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 127.57 | 229 | 10:10:23 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 60.12B | 365M | 0.1441 | 885.29 | 323.09B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 09:58:23 | 1 | 127.63 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/1/2024 | 13:07 | DJN | Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda |
| 23/1/2024 | 11:05 | DJN | Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion --.. |
| 12/1/2024 | 23:13 | DJN | Merck's Keytruda Combined with Chemoradiotherapy Gets FDA Approval to Treat.. |
| 09/1/2024 | 15:21 | DJN | Merck on Track for Record High Close -- Data Talk |
| 08/1/2024 | 19:54 | DJN | Trending: Johnson & Johnson and Merck & Co. Announce Acquisitions |
| 08/1/2024 | 13:45 | IHNW | Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs |
| 08/1/2024 | 13:12 | DJN | Merck to Buy Harpoon Therapeutics for $680 Million |
| 08/1/2024 | 11:47 | DJN | Harpoon Therapeutics Shares Take Flight Premarket on Report of Merck Deal.. |
| 20/12/2023 | 22:27 | DJN | FDA Says Merck's Chronic Cough Treatment Didn't Show Substantial Evidence.. |
| 19/12/2023 | 12:29 | DJN | Merck Gets FDA Priority Review For New Pneumococcal Vaccine |
Merck (MRK) Share Charts1 Year Merck Chart |
|
1 Month Merck Chart |
Intraday Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
